Get the Stockscreener App
166.58
1.23%
2.02
After Hours:
166.58
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $166.58, with a volume of 1.92M.
It is up +1.23% in the last 24 hours and down -1.82% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$164.56
Open:
$166.16
24h Volume:
1.92M
Relative Volume:
0.58
Market Cap:
$258.35B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
50.03
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+0.30%
1M Performance:
-1.82%
6M Performance:
-10.99%
1Y Performance:
+126.55%
1-Day Range:
$164.60
$166.81
1-Week Range:
$162.91
$169.35
52-Week Range:
$73.33
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
166.58 | 258.35B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,183.46 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
271.22 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.34 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.78 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
145.46 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca PLC Agencies, 2026 - OpenSecrets
Directors’ Deals: AstraZeneca’s Soriot in a major show of faith - Financial Times
AstraZeneca advances Friday, outperforms market - MarketWatch
AstraZeneca Gets FDA Priority Review for IMFINZI Combo - grafa.com
AstraZeneca & Fevertree Drinks: Big director share deals - Investors' Chronicle
AstraZeneca gains EU approval for asthma drug, boosting growth outlook with strong pipeline and oncology focus - Pluang
Why AstraZeneca Still Looks Underrated Despite Strong EPS Momentum (NYSE:AZN) - Seeking Alpha
AstraZeneca (LSE:AZN) Wins EU Asthma Nod For Trixeo This Week: How Big Is Respiratory Opportunity? - Kalkine Media
AstraZeneca hails US priority review for Imfinzi for bladder cancer - London South East
AstraZeneca stock slips 1.91 percent as earnings estimates rise - AD HOC NEWS
Priority review for AstraZeneca's Imfinzi in bladder cancer - marketscreener.com
AstraZeneca stock gains 0.5 percent ahead of the open - AD HOC NEWS
AstraZeneca stock rises 0.5 percent ahead of the open - AD HOC NEWS
AstraZeneca PLC Agencies, 2021 - OpenSecrets
AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market? - Yahoo Finance
AstraZeneca’s New Asthma Care Trial Signals Long-Term Upside for Respiratory Investors - TipRanks
AstraZeneca stock heads into the open after a 2.84 percent drop - AD HOC NEWS
AstraZeneca stock heads into the open after a 1.20 percent drop - ad-hoc-news.de
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
AstraZeneca stock falls 2.65 percent after the close - AD HOC NEWS
AstraZeneca wins EU label expansion for Trixeo in asthma (AZN) - Seeking Alpha
AstraZeneca slides Wednesday, underperforms market - MarketWatch
AstraZeneca's Trixeo Secures Approval for Asthma in the EU - Yahoo Finance Australia
AstraZeneca LSE:AZN EU Drug Wins Put Cancer and Autoimmune Growth in Focus - kalkinemedia.com
AstraZeneca stock slips as Trixeo wins EU asthma approval - AD HOC NEWS
EU clears first triple-therapy asthma medicine from AstraZeneca (AZN) - Stock Titan
AstraZeneca (LSE:AZN) Pipeline Wins Put Valuation in Focus - Kalkine Media
AstraZeneca wins EU approval for Trixeo asthma inhaler - proactiveinvestors.co.uk
AstraZeneca PLC Announces Trixeo Approved In EU For Asthma - TradingView
AstraZeneca’s Trixeo Aerosphere Approved In EU For Asthma - DirectorsTalk Interviews
REGAstraZeneca PLCTrixeo approved in EU for asthma - TradingView
AstraZeneca stock heads into the open after a 0.08 percent fall - AD HOC NEWS
AstraZeneca stock gains 1.22 percent at the close - AD HOC NEWS
BreakingviewsCOMMENTARY: Big Pharma growth malady has a risky cure - Reuters
AstraZeneca stock gains as Deutsche Bank raises its target - AD HOC NEWS
AZN Historical Stock Prices & Daily Price Data | AstraZeneca PLC - quiverquant.com
AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England - Insider Monkey
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance
AstraZeneca PLC (AZN) Stock Analysis: Is A 27.75% Upside On The Horizon? - DirectorsTalk Interviews
Two favorable EU opinions for AstraZeneca - marketscreener.com
AstraZeneca’s Klygefa Recommended For EU Approval In Generalised Myasthenia Gravis - DirectorsTalk Interviews
AstraZeneca PLC (AZN.L) Stock Analysis: Unveiling a 26% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
AstraZeneca PLC (Dinari Tokenized Stock)AZNStock Price & News - The Motley Fool
AstraZeneca PLC Agencies, 2024 - opensecrets.org
Long Wait Is Good Omen For AstraZeneca’s AVANZAR Lung Cancer Trial - insights.citeline.com
AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2 Positive Breast Cancer - marketscreener.com
AstraZeneca (AZN) CEO buys 60,000 shares in LON trade - Stock Titan
FDA Grants Priority Review to AstraZeneca's Efzimfotase - marketscreener.com
AstraZeneca Wins FDA Priority Review for Rare Bone Disease Drug - marketscreener.com
Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer - AstraZeneca
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks? - Yahoo Finance
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):